In vivo effects of cardiotrophin-1.
Cardiotrophin-1 (CT-1) is a recently discovered cytokine that was isolated based on its ability to induce cardiac myocyte hypertrophy in vitro. In this study, the effects of chronic administration of CT-1 to mice (0.5 or 2 microg by intraperitoneal injection, twice a day for 14 days) were determined. A dose-dependent increase in both the heart weight and ventricular weight to body ratios was observed in the treated groups. The body weights of the animals were unaffected. These results indicate that CT-1 can induce cardiac hypertrophy in vivo. CT-1 was not specific for the heart, however. It stimulated the growth of the liver, kidney, and spleen, and caused atrophy of the thymus. CT-1 administration also increased the platelet counts by 70%, with no change in mean platelet volume. Red blood cell counts were increased in the treated animals, and there was a concomitant increase in haemoglobin concentration. Thus, CT-1 has a broad spectrum of biological activities in vivo. This observation is consistent with previous in-vitro findings showing that the mRNA for CT-1 is expressed in several tissues, and that CT-1 can function through binding to the leukaemia inhibitory factor (LIF) receptor and signalling through the gp130 pathway.
Jin
H
H
Department of Cardiovascular Research, Genentech, Inc., South San Francisco, CA 94080, USA. hkj@gene.com
Yang
R
R
Keller
G A
GA
Ryan
A
A
Ko
A
A
Finkle
D
D
Swanson
T A
TA
Li
W
W
Pennica
D
D
Wood
W I
WI
Paoni
N F
NF
D000818:Animals; D001798:Blood Proteins / Q000187:drug effects; D016207:Cytokines / Q000494:pharmacology*; D005260:Female; D006321:Heart / Q000187:drug effects*; D006403:Hematologic Tests; D007668:Kidney / Q000187:drug effects; D008099:Liver / Q000187:drug effects; D051379:Mice; D013154:Spleen / Q000187:drug effects; D013950:Thymus Gland / Q000187:drug effects
D001798:Blood Proteins; D016207:Cytokines; C092073:cardiotrophin 1